LOGO
LOGO

Will ASN Spotlight On REGEN-007 Propel ProKidney Toward Accelerated Approval?

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
prok 08102025 lt

ProKidney Corp. (PROK), a pioneer in the treatment of chronic kidney disease, is set to present full results from its Phase 2 REGEN-007 trial as a late-breaking clinical presentation at the American Society of Nephrology (ASN) 2025 Kidney Week, taking place from November 5 to 9, 2025, in Houston, Texas.

The data will spotlight the company's lead autologous cell therapy candidate, rilparencel, in patients with chronic kidney disease (CKD) and type 2 diabetes.

Subscribe to continue reading the article.
This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription.
Start Free Trial
FREE 7-Day Trial - No Payment Required
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update -June 15 - June 19, 2026

June 19, 2026 16:46 ET
Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.